Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that v::RET status confers therapeutic sensitivity to Vandetanib in patients with Medullary Thyroid Cancer.
This statement is based on a regulatory approval from the Health Service Executive:
Treatment of medullary thyroid cancer (MTC) in patients with Rearranged during Transfection (RET) mutation positive, unresectable locally advanced or metastatic disease.